Management Team & Consultants

Brady Granier, BSN: CEO/President, Director

  • 4 years with BioCorRx Inc.; repositioned company as leader in the industry with the acquisition of TheraKine technology and R&D initiative, assembled a team of addiction experts worldwide, extensive experience with treatment of patients using naltrexone
  • 12 years in media sales and business development for Clear Channel Media and Entertainment; former Healthcare Category Manager
  • 9 years combined experience in the Healthcare and Behavioral Health Field

Lourdes Felix: CFO/COO, Director

  • 5 years with BioCorRx Inc.; instrumental in completing multi-million dollar equity financing, extensive experience with clinic operations management, areas of expertise; SEC filings and reporting, treasury/banking, M&A, accounting & finance, business development, general management, financial and benchmark reporting, forecasts & budgets
  • 8 years as former Controller for public accounting firm; responsible for operations and financial management
  • 20 years experience in Finance and Operations Management in the private sector, public accounting, and public company experience

Tom Welch: Vice President of Contracting & Payor Relations

  • Mr. Welch has decades of operating experience. Mr. Welch was a founder and Director of Operations at TAK Management from 2012 until 2015. TAK Management was responsible for the streamlining of clinical and financial operations for Start Fresh Alcohol and Opioid Recovery Clinic Inc. Mr. Welch led a team that completely reorganized clinic operations. Tom was also successful in negotiating reimbursement with major private insurance corporations across the U.S.
  • Prior to his tenure with TAK Management, Mr. Welch created Benchmark Consulting Group LLC in 2001 in Los Angles California and expanded into Dallas Texas in 2005. He has been actively involved in assisting in infrastructure creation including, front and back office management, billing and coding personnel, clinical management and executive teams. Tom was responsible for negotiating multiple partnership agreements and contracts with major medical corporations and both the Military and Veterans Administration

Bal S. Brar, PhD: Lead Drug Development Study Design Consultant

  • Dr. Bal S. Brar is the lead trial design consultant for BioCorRx's planned clinical trial to seek FDA approval for BICX102. He has over 25 years of experience in drug and device development. His experience includes worldwide regulatory submission of 50 INDs/510K's and 505(b)(2)'s, and approval of 8 NDA's. Dr. Brar's experience includes working with major pharmaceutical companies such as Lederle /Wyeth, GlaxoSmithKline, and Allergan. During his career, Dr. Brar participated in development efforts for Aristocort, Tazarotene, Botox, Alphagan, Lumigan, Restasis, Ofloxacin, Azelex, and Avage. He has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from India with finance training from Harvard Business School. Dr. Brar is a recipient of numerous achievements awards for excellence and belongs to a number of scientific organizations. Dr. Brar is also the author/coauthor of over 55 scientific publications

Dr. David Gastfriend: Medical Consultant

  • 9 years with Alkermes, Inc. as VP of Scientific Communication; worked on pivotal efficacy studies and research on effectiveness, health services, criminal justice systems and health economics.
  • 5 years Massachusetts General Hospital as Director of Addiction Research Program
  • 22 years Washington Circle Group non-profit as Vice President; national experts in substance abuse policy

Dr. Steven M. Weisman: Lead Clinical and Regulatory Support Consultant

  • Dr. Steven M. Weisman, a founder of Innovative Science Solutions and Head of Clinical and Regulatory Support, will play a leading role in guiding the Company through its anticipated FDA 505(b)(2) regulatory submission(s). Dr. Weisman has over 20 years of experience in pharmacology, toxicology, pharmaceutical product development, clinical and regulatory affairs, and marketing evaluation. As head of ISS' Clinical and Regulatory Support practice, he manages all aspects of the FDA advisory committee process for many of the largest pharmaceutical companies and represents companies before regulatory authorities around the world. He played a leading role to the removal of PPA (phenylpropanolamine) and analgesic Aleve, from a prescription-only product to over-the-counter form. Dr. Weisman received his PhD in Pharmacology from Cornell University Medical College and completed his postdoctoral training in Immunopharmacology at the Roche Institute of Molecular Biology

Priya Jambhekar: Drug Regulatory Consultant

  • Ms. Jambhekar is a drug development entrepreneur with over 25 years of executive experience in worldwide regulatory, quality, clinical and pharmacovigilance operations, as well as early and late stage development product registration and commercial support. She has held positions including Global Senior Vice President of Regulatory & Quality Operations at Paramount BioSciences, Global Vice President at Ethicon, a Johnson & Johnson company, and Worldwide Vice President of Regulatory and Government Relations at Alkermes. Other senior positions include Baxter ACC, as Regulatory Head of Compliance, and Bristol-Myers Squibb, as Manager of Regulatory, Safety, Compliance. She is also certified by the Regulatory Affairs Professional Society and the New Jersey Pharmaceutical Quality Control and Assurance Society

Bruce Firestone, PhD: CMC Expert Consultant

  • Dr. Firestone has over three decades of pharmaceutical research & development experience with on-time delivery of over 15 product approvals as new chemical entities and line extensions. Dr. Firestone is an accomplished author with over 40 publications, abstracts and patents. He also has extensive chemistry, manufacturing and controls (CMC) expertise with: small molecules, drug and drug-device combinations, sustained-release products, semisolids, topical and intravitreal routes of administration. He has held senior positions at Allergan and is an expert in pharmaceutical product development, manufacturing process development and scale-up, technology transfer, process validation, risk management, technology assessment, due diligence, CMC documentation, and CMC strategy